Detailed company information
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 13, 2026
Earnings Transcript for 2026 - Q1Released: May 11, 2026
Earnings Transcript for 2025 - Q4Released: Mar 16, 2026
Earnings Transcript for 2025 - Q3Released: Nov 10, 2025
Earnings Transcript for 2025 - Q2Released: Aug 11, 2025
Earnings Transcript for 2025 - Q1Released: May 12, 2025
Earnings Transcript for 2024 - Q4Released: Mar 17, 2025
Earnings Transcript for 2024 - Q3Released: Nov 12, 2024
Earnings Transcript for 2024 - Q2Released: Aug 09, 2024
Earnings Transcript for 2024 - Q1Released: May 06, 2024
Earnings Transcript for 2023 - Q4Released: Feb 26, 2024
Earnings Transcript for 2023 - Q3Released: Nov 06, 2023
Earnings Transcript for 2023 - Q2Released: Aug 07, 2023
Earnings Transcript for 2023 - Q1Released: May 08, 2023
Earnings Transcript for 2022 - Q4Released: Feb 27, 2023
Earnings Transcript for 2022 - Q3Released: Nov 07, 2022
Earnings Transcript for 2022 - Q2Released: Aug 08, 2022
Earnings Transcript for 2022 - Q1Released: May 09, 2022
Earnings Transcript for 2021 - Q4Released: Feb 28, 2022
Earnings Transcript for 2021 - Q3Released: Nov 09, 2021
Earnings Transcript for 2021 - Q2Released: Aug 09, 2021
Earnings Transcript for 2021 - Q1Released: May 10, 2021
Earnings Transcript for 2020 - Q4Released: Mar 01, 2021
Earnings Transcript for 2020 - Q3Released: Nov 08, 2020